An interventional study of BrudyGlauco and Placebo in Glaucoma, Primary Open Angle Glaucoma (POAG) and Neuroprotection, sponsored by Institut Catala de Retina. Recruiting at 2 sites in Spain. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Institut Catala de Retina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.
Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 17th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2025, is one of 18 with no phase, and was the 46th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:
Santen SAS · Sites in Spain, Austria, Belgium and 5 more countries
Ages 18–85
Elios Vision, Inc. · Sites in Spain, Belgium, France and 3 more countries
Ages 40+
Nova Eye, Inc. · Sites in Spain, Germany, United Kingdom
Ages 22+
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Sites in Spain
Ages 18–99
iSTAR Medical · Sites in Spain, Panama, United Kingdom
Ages 40+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 9
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 107 across the 35 interventional studies, 198 across the 12 observational. Of the 35 that completed or were terminated, 16 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 47 have an industry lead sponsor. The 10 most frequent:
Institut Catala de Retina is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Institut Catala de Retina has 2 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma, Open-Angle with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04524416iSTAR MedicalMINIject Global Long-Term Follow-up Study | 2026-12 |
| NCT05786196Nova Eye, Inc.Multicenter Glaucoma Study Investigating Standalone Canaloplasty | 2026-12 |
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.
This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence.
The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function.
The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.
This study investigates the potential neuroprotective or neuromodulatory effects of BrudyGlauco, a nutritional supplement containing docosahexaenoic acid (DHA) and citicoline, in patients with glaucoma. Glaucoma is a progressive optic neuropathy that leads to visual field deterioration and, in severe cases, to blindness. Although current treatments primarily target intraocular pressure (IOP), the progression of vision loss in glaucoma could benefit by therapies aimed at protecting the optic nerve.
This randomized, double-blind, placebo-controlled trial will assess the effects of BrudyGlauco on visual function over 12 months, with the primary outcome focusing on changes in visual field function. Secondary outcomes include treatment safety, tolerance, and the persistence of any observed effects after treatment discontinuation.
Participants will be recruited from Institut Català de Retina (ICR) and Hospital de la Esperanza, where they will undergo regular ophthalmologic evaluations. These evaluations include visual field tests to measure any changes in vision and DHA biomarker analysis using the Dry Blood Spot (DBS) method to assess DHA levels in erythrocyte membranes.
An interim analysis at six months will allow for an early assessment of efficacy and safety. The final results will determine whether BrudyGlauco has neuroprotective potential for glaucoma management, offering insights into its ability to protect the optic nerve and potentially improve quality of life for patients living with the disease.
Glaucoma is one of the leading causes of blindness worldwide, and current treatments that focus on lowering IOP are not always sufficient to prevent the progressive loss of vision. This study will explore whether DHA and citicoline, known for their neuroprotective properties, can offer additional benefits beyond traditional treatments.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's planned enrollment of 108 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Institut Catala de Retina is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glaucoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria:
Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography.
Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field.
Exclusion Criteria:
Any condition that could alter visual field testing, including:
Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive BrudyGlauco (DHA + Citicoline) orally, taking two capsules at lunchtime for 12 months.
Dietary Supplement: BrudyGlauco
Participants receive placebo (sunflower oil capsules) orally, taking two capsules at lunchtime for 12 months.
Dietary Supplement: Placebo
Participants in the experimental group will receive BrudyGlauco, a dietary supplement containing docosahexaenoic acid (DHA) and citicoline.
Participants in the placebo comparator group will receive identical-looking capsules containing sunflower oil.
Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months
Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months
Time frame: 12 months
Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months
Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months
Time frame: 12 months
Rate of change (slope) in Visual Field Index (VFI) before, during, and after treatment
Rate of change (slope) in Visual Field Index (VFI) before, during, and after treatment
Time frame: Baseline, 6 months, 12 months, and 3 months post-treatment (15 months total)
Rate of change (slope) in Mean Deviation (MD) before, during, and after treatment
Rate of change (slope) in Mean Deviation (MD) before, during, and after treatment
Time frame: Baseline, 6 months, 12 months, and 3 months post-treatment (15 months total).
Incidence of treatment-emergent adverse events during BrudyGlauco treatment
Incidence of treatment-emergent adverse events during BrudyGlauco treatment
Time frame: 12 months
Change from baseline in Visual Field Index (VFI) at 6 months
Change from baseline in Visual Field Index (VFI) at 6 months
Time frame: 6 months
Incidence of adverse events at 6 months
Incidence of adverse events at 6 months
Time frame: 6 months
Change in Mean Deviation (MD) 3 months after treatment discontinuation
Change in Mean Deviation (MD) 3 months after treatment discontinuation
Time frame: 3 months post-treatment (15 months total).
Change in Visual Field Index (VFI) 3 months after treatment discontinuation
Change in Visual Field Index (VFI) 3 months after treatment discontinuation
Time frame: 3 months post-treatment (15 months total).
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.
Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 24 months is below that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Catala de Retina